Primary CNS Lymphoma vs Toxoplasmosis

Quick Answer

In an immunocompromised patient (classically AIDS) with a ring-enhancing brain lesion, the central question is primary CNS lymphoma (PCNSL) versus toxoplasmosis — treated completely differently (chemotherapy/radiation vs anti-parasitic therapy). Functional imaging separates them by metabolism: PCNSL is hypermetabolic — FDG-avid and thallium-201-avid, while toxoplasmosis is an infection/abscess that is typically non-avid (cold) on thallium and low on FDG. So an avid lesion favors lymphoma and a non-avid lesion favors toxoplasmosis, complementing the MRI and clinical context (Toxoplasma serology, response to empiric anti-toxoplasma therapy).

The metabolic discriminator

PCNSL is a hypercellular, highly metabolic tumour → increased FDG uptake and increased thallium-201 uptake. Toxoplasmosis is an inflammatory/abscess process → little thallium uptake and generally low FDG. Thus increased uptake favours lymphoma; absent/low uptake favours toxoplasmosis. Thallium-201 brain SPECT was the classic tool for exactly this question; FDG-PET serves the same role with better resolution.

Supporting points: a single lesion, periventricular/subependymal location, and subependymal spread favour lymphoma; multiple lesions and a positive Toxoplasma serology favour toxoplasmosis. Empiric anti-toxoplasma therapy with follow-up imaging is a standard confirmatory step — lack of response raises suspicion for lymphoma and prompts biopsy.

Caveats

The distinction is probabilistic, not absolute: other infections and treatment effects can confound, steroids can transiently shrink lymphoma ("ghost tumour") and reduce avidity, and small or necrotic lesions are harder to characterise. Functional imaging raises or lowers the probability and guides whether to pursue empiric anti-toxoplasma treatment versus biopsy — it does not replace tissue when management hinges on certainty.

Common Pitfalls / Cautions

• Steroids can mask lymphoma (shrinking it and reducing uptake) — imaging after steroids may underestimate disease.
• Necrotic/treated lesions and coexisting infection blur the pattern.
• Interpret with MRI, serology, and response to empiric therapy — not uptake alone.

Board Pearls

• In AIDS the two dominant ring-enhancing lesions are toxoplasmosis (most common) and PCNSL; because MRI appearances overlap, functional imaging is the key noninvasive discriminator.
• Adding CSF EBV DNA to thallium/FDG avidity increases specificity for PCNSL in the immunocompromised.
• Thallium-201 delayed retention characterizes lymphoma; thallium brain SPECT was the classic tool, now largely replaced by higher-resolution FDG-PET.
• AIDS-related PCNSL is nearly always EBV-driven diffuse large B-cell lymphoma; whole-body FDG-PET screens for systemic lymphoma that would change management.

Differential Diagnosis

• Toxoplasmosis — typically multiple lesions at the basal ganglia/corticomedullary junction with positive serology; non-avid.
• PCNSL — often a single periventricular/subependymal avid lesion.
• Other opportunistic infections — tuberculoma, cryptococcoma, and bacterial/fungal abscess (generally low uptake, though granulomas can be variably avid).
• Progressive multifocal leukoencephalopathy (PML) — typically non-enhancing white-matter disease, a distinct pattern.
• Metastasis or other primary tumor — considered when the clinical setting is not classic AIDS.

Reporting Checklist

• State lesion number and location (periventricular/subependymal vs basal ganglia) and whether solitary or multiple.
• Report FDG/thallium uptake relative to normal cortex/background and give a lymphoma-versus-toxoplasmosis probability, not a definitive call.
• Note steroid exposure and timing, which may mask lymphoma.
• Integrate Toxoplasma serology, CD4 count, and CSF EBV where available.
• Recommend the next step — empiric anti-toxoplasma therapy with follow-up imaging versus biopsy.

Self-Check

Key References

• Studies of thallium-201 SPECT and FDG-PET differentiating primary CNS lymphoma from toxoplasmosis in immunocompromised patients.
• Reviews of the ring-enhancing-lesion differential and the role of empiric anti-toxoplasma therapy with follow-up imaging.